New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology’s annual meeting, Dec. 5-8, including: Actinium, Allogene, Allovir, Amgen, Amphivena, Apellis, Arch Oncology, Astrazeneca, Attralus, Autolus, Beigene, Bergenbio, Biocryst, Bioniz, Bluebird, BMS, Cellectis, Constellation, Corvus, Crispr, Fate, Fulcrum, Gamida, GBT, Genentech, Gilead, Glycomimetics, IGM, Immunogen, IMV, Intellia, Janssen, Kite, Kura, Lilly, Macrogenics, Magenta, Orca Bio, Poseida, Regeneron, Rhizen, Rocket, Syndax, Syros, Vertex, Viracta.

Cambridge, Mass.-based Agios Therapeutics Inc.’s encouraging phase III data from a pair of trials with allosteric activator mitapivat in pyruvate kinase deficiency brought more attention to the space, where Rocket Pharmaceuticals Inc. – at a much earlier stage – is trying a gene therapy called RP-L301.